MedTrace Logo

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer

NCT00470184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-11-25

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with radiation therapy works in treating patients undergoing surgery for stage II, stage III, or stage IV esophageal cancer.

Conditions

  • Esophageal Cancer

Interventions

DRUG

capecitabine

Oral

DRUG

oxaliplatin

IV

GENETIC

gene expression analysis

Correlative Study

GENETIC

microarray analysis

Correlative Study

GENETIC

reverse transcriptase-polymerase chain reaction

Correlative Study

PROCEDURE

adjuvant therapy

Metastatic growth control

PROCEDURE

biopsy

Examination of tissue type

PROCEDURE

conventional surgery

Tissue removal

PROCEDURE

neoadjuvant therapy

Tumor shrinkage

PROCEDURE

quality-of-life assessment

Correlative Study

RADIATION

radiation therapy

Undergoing radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Nikhil Khushalani, MD · Roswell Park Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00470184 on ClinicalTrials.gov